Doxorubicin Liposomal 71 MG / D5W IVPB recalled over sterility concerns
- Recall date
- June 12, 2019
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Infusion Options, Inc. recalls Doxorubicin Liposomal 71 MG / 250 ML D5W IVPB; Doxorubicin Liposomal 66 MG/250 ML D5W, Rx Only, Infusion Options, Inc.…
- Recall number
- D-1771-2019
- FDA classification
- Class II
- Brand / firm
- Infusion Options, Inc.
- Sold / distributed
- NY only
Why it was recalled
Lack of Assurance of Sterility
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Doxorubicin Liposomal 71 MG / 250 ML D5W IVPB; Doxorubicin Liposomal 66 MG/250 ML D5W, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233 Doxorubicin 16 MG/1000 ML NS IV WITH Vincristine 0.6 MG and Etoposide 78 MG Doxorubicin 16 MG/1000 ML NS IV WITH Vincristine 0.6 MG and Etoposide 78 MG Duplicate Doxorubicin 45 MG / 22.5 ML IVP SYRINGE
Get recall alerts
Free email alert whenever Infusion Options, Inc. has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Infusion Options, Inc.